中国普外基础与临床杂志

中国普外基础与临床杂志

TERT 启动子突变与甲状腺乳头状癌临床病理学特征关系的研究进展

查看全文

引用本文: 殷德涛, 余坤. TERT 启动子突变与甲状腺乳头状癌临床病理学特征关系的研究进展. 中国普外基础与临床杂志, 2018, 25(10): 1157-1160. doi: 10.7507/1007-9424.201808101 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin, 2018, 68(1): 7-30.
2. Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China, 2013. Cancer Lett, 2017, 401: 63-71.
3. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
4. Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol, 2013, 2013: 965212.
5. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg, 2014, 140(4): 317-322.
6. 杨雷, 郑荣寿, 王宁, 等. 2013 年中国甲状腺癌发病与死亡情况. 中华肿瘤杂志, 2017, 39(11): 862-867.
7. Hughes DT, Haymart MR, Miller BS, et al. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid, 2011, 21(3): 231-236.
8. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev, 2002, 66(3): 407-425.
9. 刘晓莉. 甲状腺癌 TERT 启动子突变的筛查与临床相关性分析. 长春: 吉林大学, 2013.
10. Mengual Gómez DL, Armando RG, Farina HG, et al. Telomerase and telomere: their structure and dynamics in health and disease. Medicina (B Aires), 2014, 74(1): 69-76.
11. 殷德涛, 余坤. TERT 启动子突变在甲状腺癌中的研究进展. 国际外科学杂志, 2015, 42(11): 768-771.
12. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science, 2013, 339(6122): 959-961.
13. Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer, 2013, 20(4): 603-610.
14. Jin L, Chen E, Dong S, et al. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget, 2016, 7(14): 18346-18355.
15. Myung JK, Kwak BK, Lim JA, et al. TERT promoter mutations and tumor persistence/recurrence in papillary thyroid cancer. Cancer Res Treat, 2016, 48(3): 942-947.
16. Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol, 2014, 32(25): 2718-2726.
17. Gandolfi G, Ragazzi M, Frasoldati A, et al. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur J Endocrinol, 2015, 172(4): 403-413.
18. Vuong HG, Altibi AM, Duong UN, et al. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis. Tumour Biol, 2017, 39(10): 1010428317713913.
19. George JR, Henderson YC, Williams MD, et al. Association of TERT promoter mutation, but not BRAF mutation, with increased mortality in PTC. J Clin Endocrinol Metab, 2015, 100(12): E1550-E1559.
20. Yeung MJ, Serpell JW. Management of the solitary thyroid nodule. Oncologist, 2008, 13(2): 105-112.
21. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016, 26(1): 1-133.
22. Alzahrani AS, Alsaadi R, Murugan AK, et al. TERT promoter mutations in thyroid cancer. Horm Cancer, 2016, 7(3): 165-177.
23. Yin DT, Yu K, Lu RQ, et al. Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis. Clin Endocrinol (Oxf), 2016, 85(2): 299-305.
24. Liu C, Liu Z, Chen T, et al. TERT promoter mutation and its association with clinicopathological features and prognosis of papillary thyroid cancer: a meta-analysis. Sci Rep, 2016, 6: 36990.
25. Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin, 2018, 68(1): 55-63.
26. Jin A, Xu J, Wang Y. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer. Medicine (Baltimore), 2018, 97(29): e11548.
27. Censi S, Cavedon E, Bertazza L, et al. Frequency and significance of promoter, and mutations in cytologically indeterminate thyroid nodules: a monocentric case series at a tertiary-level endocrinology unit. Front Endocrinol (Lausanne), 2017, 8: 273.
28. Liu R, Xing M. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocr Relat Cancer, 2014, 21(5): 825-830.
29. Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab, 2014, 99(5): E754-E765.
30. Vinagre J, Almeida A, Pópulo H, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun, 2013, 4: 2185.
31. Lee SE, Hwang TS, Choi YL, et al. Prognostic significance of TERT promoter mutations in papillary thyroid carcinomas in a BRAF(V600E) mutation-prevalent population. Thyroid, 2016, 26(7): 901-910.
32. Decaussin-Petrucci M, Descotes F, Depaepe L, et al. Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy. Cytopathology, 2017, 28(6): 482-487.
33. Sassolas G, Hafdi-Nejjari Z, Ferraro A, et al. Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid, 2012, 22(1): 17-26.
34. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1 056 FNA samples. J Clin Endocrinol Metab, 2011, 96(11): 3390-3397.
35. de Biase D, Gandolfi G, Ragazzi M, et al. TERT promoter mutations in papillary thyroid microcarcinomas. Thyroid, 2015, 25(9): 1013-1019.
36. Yabuta T, Matsuse M, Hirokawa M, et al. TERT promoter mutations were not found in papillary thyroid microcarcinomas that showed disease progression on active surveillance. Thyroid, 2017, 27(9): 1206-1207.
37. Ren H, Shen Y, Hu D, et al. Co-existence of and promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. Cancer Manag Res, 2018, 10: 1005-1013.
38. Su X, Jiang X, Wang W, et al. Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis. Onco Targets Ther, 2016, 9: 6965-6976.